Author:
Dimitrova Rozalina,James Lynn,Liu Chengcheng,Orejudos Amelia,Yushmanova Irina,Brin Mitchell F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference34 articles.
1. Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci. 2014;1329(1):67–80.
2. BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103000s5309lbl.pdf. Accessed Feb 2020.
3. Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(10):4283–93.
4. Rovner E, Kohan A, Chartier-Kastler E, Jünemann KP, Del Popolo G, Herschorn S, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196(3):801–8.
5. Guerzoni S, Pellesi L, Baraldi C, Pini LA. Increased efficacy of regularly repeated cycles with onabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain. 2015;17(1):48.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献